文献速递消化道肿瘤与早癌消化内镜

囊性纤维化患者结直肠癌筛查的成本效益分析

Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
PubMed 文献 · Gastroenterology · 2017-12-27

该研究调整Microsimulation Screening Analysis-Colon微模拟模型,以反映囊性纤维化患者结直肠癌风险升高和预期寿命降低,分别对从未接受器官移植和已接受器官移植的患者建模76种结肠镜筛查策略。以每获得1个生命年支付10万美元的支付意愿阈值为标准,从未移植者每5年一次从40岁开始结肠镜筛查为最优策略,可预防79%的结直肠癌死亡;已移植者最优结肠镜筛查应从30岁或35岁开始,取决于移植时年龄。每年一次粪便免疫化学检测(FIT)筛查被预测具有成本效益,但FIT在人群中的准确性水平尚不明确。

要点

  • 从未接受器官移植的囊性纤维化患者,每5年一次从40岁开始结肠镜筛查为最优结肠镜策略,可预防79%的结直肠癌死亡。
  • 已接受器官移植的囊性纤维化患者,最优结肠镜筛查应从30岁或35岁开始,取决于移植时年龄。
  • 每年一次FIT筛查被预测对囊性纤维化患者具有成本效益,但FIT在人群中的准确性水平尚不明确。

核心结论

  • 使用Microsimulation Screening Analysis-Colon微模拟模型发现,对囊性纤维化患者进行结直肠癌筛查具有成本效益。
  • 由于这些患者结直肠癌风险较高,筛查应更早开始且筛查间隔更短。
  • 本研究结果(尤其是FIT筛查相关结果)可能受限于囊性纤维化患者可用证据有限。

研究设计与样本

  • 调整现有Microsimulation Screening Analysis-Colon微模拟模型以反映囊性纤维化患者结直肠癌风险升高和预期寿命降低。
  • 分别对从未接受器官移植的个体和已接受器官移植的患者进行建模。
  • 建模了76种结肠镜筛查策略,变化年龄范围和筛查间隔。
  • 以每获得1个生命年支付10万美元的支付意愿阈值确定最优筛查策略。
  • 进行敏感性和补充分析,包括以粪便免疫化学检测(FIT)作为替代检测、更早的移植年龄和结肠镜并发症发生率增加,以评估最优筛查策略是否改变。

主要发现

  • 对于从未接受器官移植的囊性纤维化患者,每5年一次从40岁开始结肠镜筛查为最优结肠镜策略,该策略预防了79%的结直肠癌死亡。
  • 对于已接受器官移植的囊性纤维化患者,最优结肠镜筛查应从30岁或35岁开始,取决于患者移植时年龄。
  • 每年一次FIT筛查被预测对囊性纤维化患者具有成本效益,但FIT在人群中的准确性水平尚不明确。

关键数值与推荐

  • 支付意愿阈值为每获得1个生命年10万美元。
  • 从未接受器官移植者最优结肠镜策略:每5年一次,从40岁开始,预防79%的结直肠癌死亡。
  • 已接受器官移植者最优结肠镜筛查开始年龄:30岁或35岁,取决于移植时年龄。
  • 每年一次FIT筛查被预测具有成本效益,但FIT在人群中的准确性水平尚不明确。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究结果(尤其是FIT筛查相关结果)可能受限于囊性纤维化患者可用证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Individuals with cystic fibrosis are at increased risk of colorectal cancer (CRC) compared to the general population, and risk is higher among those who received an organ transplant. We performed a cost-effectiveness analysis to determine optimal CRC screening strategies for patients with cystic fibrosis. METHODS: We adjusted the existing Microsimulation Screening Analysis-Colon microsimulation model to reflect increased CRC risk and lower life expectancy in patients with cystic fibrosis. Modeling was performed separately for individuals who never received an organ transplant and patients who had received an organ transplant. We modeled 76 colonoscopy screening strategies that varied the age range and screening interval. The optimal screening strategy was determined based on a willingness to pay threshold of $100,000 per life-year gained. Sensitivity and supplementary analyses were performed, including fecal immunochemical test (FIT) as an alternative test, earlier ages of transplantation, and increased rates of colonoscopy complications, to assess whether optimal screening strategies would change. RESULTS: Colonoscopy every 5 years, starting at age 40 years, was the optimal colonoscopy strategy for patients with cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths from CRC. Among patients with cystic fibrosis who had received an organ transplant, optimal colonoscopy screening should start at an age of 30 or 35 years, depending on the patient's age at time of transplantation. Annual FIT screening was predicted to be cost-effective for patients with cystic fibrosis. However, the level of accuracy of the FIT in population is not clear. CONCLUSIONS: Using a Microsimulation Screening Analysis-Colon microsimulation model, we found screening of patients with cystic fibrosis for CRC to be cost-effective. Due to the higher risk in these patients for CRC, screening should start at an earlier age with a shorter screening interval. The findings of this study (especially those on FIT screening) may be limited by restricted evidence available for patients with cystic fibrosis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gini A, Zauber AG, Cenin DR, et al. Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology. 2017. PMID: 29288655. doi:10.1053/j.gastro.2017.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。